A study of a new medicine for liver disease in adults with extra body weight and liver fat
Part of Digestive system clinical trials.
This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 69 years old.
- Your body mass index (BMI) is between 27 and 40 (calculated from your height and weight).
- You have at least 8% fat in your liver, measured by a special MRI scan.
- You have never been diagnosed with a more serious liver condition called MASH (metabolic dysfunction-associated steatohepatitis).
- You have not used certain weight-loss or diabetes medicines (like liraglutide, semaglutide, or pioglitazone) in the last 6 months.
- You are not taking high-dose vitamin E (over 800 IU per day) or certain other medicines for liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests a new medicine (NNC6989-0001) for people who are overweight or have obesity. It checks if the medicine is safe and how the body handles it. If eligible, you would receive the study drug and be monitored closely.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests a new experimental drug called OPK-88006 to see if it can help treat MASH, a serious liver condition linked to excess fat buildup. The study has two parts: one with healthy volunteers to check safety, and one with people who have signs of fatty liver disease.
This study tests a new medicine to see how well it helps people with excess body weight lose weight. It may be an option if you have tried to lose weight through dieting before but haven't had lasting success.
Hear when a new Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.